Septerna rises after Wells Fargo upgrades to 'overweight'

Septerna

14/11/2025 13:19

** Shares of drug developer Septerna  SEPN.O up ~2% at $19.55 premarket

** Wells Fargo upgrades stock to "overweight" from "equal weight," PT to $28 from $18

** Brokerage says it is confident on co's SEP-479's (oral PTH1R) safety profile, differentiation relative to co's prior program

** SEPN's study conducted on cynomolgus monkeys (cyno study) for compound called SEP-479 will prove it does not have bilirubin issues compared to previous drug SEP-786, which showed increase in bilirubin levels, brokerage says

** Wells Fargo says phase 1 results for co's SEP-631 compound will be important near-term catalyst, alongside SEP-479 compound coming out in late 2026

** As of last close, stock down ~16%, YTD

 (Reporting by Koyena Das)

 ((koyena.das@thomsonreuters.com))